Do you want to read an article? Please log in or register.
Baseline serum CXCL10 and IL-12 levels may predict severe asthmatics' responsiveness to omalizumab
Asthma
Related content
Asthma
Serum Reactive Oxygen Metabolite Levels Predict Severe Exacerbations of Asthma
PLoS One.
Nakamoto K, Watanabe M, Sada M, Inui T, Nakamura M, Honda K, Wada H, Mikami Y, Matsuzaki H, Horie M, Noguchi S, Yamauchi Y, Koyama H, Kogane T, Kohyama T, Takizawa H
doi: 10.1371/
COPD
Serum levels of hyaluronic acid are associated with COPD severity and predict survival
Eur Respir J.
Papakonstantinou E, Bonovolias I, Roth M, Tamm M, Schumann D, Baty F, Louis R, Milenkovic B, Boersma W, Stieltjes B, Kostikas K, Blasi F, Aerts JG, Rohde GGU, Lacoma A, Torres A, Welte T, Stolz D
doi: 10.1183/13993003.
RECOMMENDED
Asthma
"T2-high" in severe asthma related to blood eosinophil, exhaled nitric oxide and serum periostin
Eur Respir J.
Pavlidis S, Takahashi K, Ng Kee Kwong F, Xie J, Hoda U, Sun K, Elyasigomari V, Agapow P, Loza M, Baribaud F, Chanez P, Fowler SJ, Shaw DE, Fleming LJ, Howarth PH, Sousa AR, Corfield J, Auffray C, De Meulder B, Knowles R, Sterk PJ, Guo Y, Adcock IM, Djukanovic R, Fan Chung K, on behalf of the U-BIOPRED Study Group
doi: 10.1183/13993003.
RECOMMENDED
Asthma
Sub-optimal treatment response to anti-IL-5 monoclonal antibodies in severe eosinophilic asthmatics with airway autoimmune phenomena
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 3
Recommended by
Dr Marcus Hesse, Faculty Member
Eur Respir J.
Mukherjee M, Forero DF, Tran S, Boulay ME, Bertrand M, Bhalla A, Cherukat J, Al-Hayyan H, Ayoub A, Revill SD, Javkar T, Radford K, Kjarsgaard M, Huang C, Dvorkin-Gheva A, Ask K, Olivenstein R, Dendukuri N, Lemiere C, Boulet LP, Martin JG, Nair P
doi: 10.1183/13993003.00117-2020.
AsthmaCOPD
Omalizumab Treatment Response in a Severe Allergic Asthma Population with Overlapping COPD
Chest.
Maltby S, Gibson PG, Powell H, McDonald VM
doi: 10.1016/
Effectiveness and response predictors of omalizumab in a severe allergic asthma population with a high prevalence of comorbidities: the Australian Xolair Registry
Intern Med J.
Gibson PG, Reddel H, McDonald VM, Marks G, Jenkins C, Gillman A, Upham J, Sutherland M, Rimmer J, Thien F, Katsoulotos GP, Cook M, Yang I, Katelaris C, Bowler S, Langton D, Robinson P, Wright C, Yozghatlian V, Burgess S, Sivakumaran P, Jaffe A, Bowden J, Wark PA, Yan KY, Kritikos V, Peters M, Hew M, Aminazad A, Bint M, Guo M
doi: 10.1111/imj.13166.
RECOMMENDED
Asthma
Treatment Benefit with Omalizumab in Children by Indicators of Asthma Severity
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
doi: 10.1016/j.jaip.2020.03.033.
AsthmaCOPD
Role for NLRP3 Inflammasome-mediated, IL-1β-Dependent Responses in Severe, Steroid-Resistant Asthma
Am J Respir Crit Care Med.
Kim RY, Pinkerton JW, Essilfie AT, Robertson AAB, Baines KJ, Brown AC, Mayall JR, Ali MK, Starkey MR, Hansbro NG, Hirota JA, Wood LG, Simpson JL, Knight DA, Wark PA, Gibson PG, O'Neill LAJ, Cooper MA, Horvat JC, Hansbro PM
doi: 10.1164/rccm.
RECOMMENDED
COPD
Change in blood eosinophils following treatment with inhaled corticosteroids may predict long-term clinical response in COPD
★ 3
Recommended by
Dr Martin Frey, Faculty Member
Eur Respir J.
Mathioudakis AG, Bikov A, Foden P, Lahousse L, Brusselle G, Singh D, Vestbo J
doi: 10.1183/13993003.02119-2019.